-
Posted by
Two Blokes May 6 -
Filed in
Stock
-
1 view
Axsome Therapeutics reported strong Q1 2025 earnings, with revenue and EPS beats driven by Auvelity and Sunosi, despite high SG&A expenses and net loss. Auvelity shows promising growth in the competitive depression market, but its success is heavily reliant on aggressive marketing and significant spending. Upcoming launches and regulatory submissions for Symbravo, AXS-14, AXS-05, and AXS-12 face stiff competition and potential regulatory hurdles.
